Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies.
Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies.The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine.Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 5, 2020 | Series C | $35M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Kite Pharma | — | Series C |